Attention CIDP Patients in Canada, UK, Germany, France, Italy and Spain
Baxalta/ IQVIA CIDP Treatment Trial, Now Enrolling Patients Wordwide
Announcing a new study to investigate a potential new medication for CIDP patients. The ADVANCE-CIDPTM 1 study is looking at a potential new treatment (an investigational medication) for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It will assess if the investigational medication could help to prevent muscle weakness in the upper and lower limbs. The investigational medication is an immunoglobulin (made from proteins found in the body called antibodies) and is given as an infusion under the skin every 2, 3, or 4 weeks.
About the study
The study is currently looking for 170 patients at approximately 90 study centers worldwide. Countries include US, Canada, UK, Germany, France, Italy and Spain. If you take part, you may be involved in the study for up to 14 months. The study is now enrolling. Requirements include:
- Must be 18 years of age or older
- Must have been diagnosed with CIDP
- Must have been receiving treatment with immunoglobulin infusions at a stable dose, every 2– 6 weeks, for at least 12 weeks (3 months).
If you live in any of the countries listed below, and are interested in participating or learning more, please contact the study team directly by using the links below.
(Coming Soon: US trial sites will be announced in Q3 of 2019. Stay tuned for updates.)
Canada
UK
Germany
France
Italy
Spain
Please visit clinicaltrials.gov and search for study identifier NCT02549170 for more information. For a list of participating countries and study centers, click on Contacts and Locations.
